Type of intervention | Effects on health outcomes (Intervention group–Control group) a | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Cognition | n | Activity functions | n | Global deterioration | n | BPSD | n | Health utility | n | QALY | |
(01) Drugs for Alzheimer’s disease | ||||||||||||
Acetylcholinesterase inhibitors | 6c | 0.561*** (0.277, 0.846) | 6c | 0.450*** (0.240, 0.661) | 3 | 0.306*** (0.181, 0.432) | 4c | 0.238* (0.052, 0.424) | 1b | − 0.323 (− 0.781, 0.136) | 2c | 0.341 (− 0.136, 0.818) |
Memantine | 2 | 0.602*** (0.290, 0.914) | 2 | 0.445*** (0.208, 0.682) | 1b | 0.337 (0.043, 0.631) | 1b | 0.618 (0.217, 1.019) | 1b | 0.224 (− 0.170, 0.618) | 1b | 0.327 (− 0.068, 0.772) |
Propentofylline | 1b | 0.228 (0.057, 0.398) | 1b | 0.212 (0.041, 0.382) | 1b | 0.207 (0.036, 0.377) | 0 | – | 0 | – | 0 | – |
Combination therapy | 1b | 0.376 (− 0.022, 0.775) | 1b | 0.118 (− 0.278, 0.513) | 0 | – | 1b | 0.568 (0.166, 0.971) | 1b | 0.249 (− 0.148, 0.646) | 1b | 0.092 (− 0.303, 0.488) |
(02) Drugs for neuropsychiatric symptoms of dementia | ||||||||||||
Antipsychotics | 0 | – | 3 | − 0.192* (− 0.369, − 0.014) | 3 | 0.189 (− 0.014, 0.392) | 0 | – | 3 | − 0.022 (− 0.225, 0.181) | 3 | 0.020 (− 0.183, 0.223) |
Antidepressants | 2 | − 0.383* (− 0.762, − 0.003) | 2 | − 0.242 (− 0.560, 0.076) | 0 | – | 2 | 0.035 (− 0.278, 0.347) | 2 | 0.006 (− .368, 0.379) | 2 | 0.378* (0.002, 0.754) |